Transduced human cell lines expressing high levels of native HIV-1 Envelope on their surface membrane, in the unmodified or interdomain stabilized form. These cell lines provide a stable source of native HIV-1 envelope for multiple uses, including the high-efficiency production of virus-like particles (VLPs) for use as vaccines, testing new inhibitors or neutralizing antibodies, or identifying/capturing B cells that produce broadly neutralizing antibodies from infected/vaccinated humans or animals.
This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.
- High-efficiency production of virus-like particles (VLPs)
- A means to test new inhibitors or neutralizing antibodies targeting HIV-1 envelope trimers
- Probe for identifying/capturing B cells that produce broadly neutralizing antibodies
- The interdomain-stabilized form does not bind CD4 and is locked in the native prefusion form